The latest version of the national medical insurance catalog has recently been released. In order to further promote the development of breast cancer prevention and treatment, let the whole society care about women's health and pay attention to cancer prevention and treatment, recently, the Guangdong Health Science Popularization Trip "Jointly Enter the Era of breast cancer Chronic Disease Management" activity was successfully held. The activity was carried out in the way of "online+offline". On the one hand, many medical experts carried out breast cancer science popularization through the network platform, and on the other hand, the event sponsor and media reporters went to the front lines of major hospitals in Guangdong Province to carry out in-depth dialogues on breast cancer prevention and treatment, the efficacy of trastuzumab "subcutaneous preparations", health care under the new medical insurance catalog and other topics. Medical experts from Guangzhou, Foshan, Yangjiang, Zhongshan, Heyuan, Shantou, Chaozhou, Jieyang and other places participated in this science popularization activity, including well-known breast health experts in Guangdong Province. Interview experts: Xu Fei, Jia Weijuan, and Yang Chunmin. Expert: Xu Fei, Professor of Internal Medicine at the Cancer Prevention and Treatment Center of Sun Yat sen University, Chief Physician, Expert: Jia Weijuan, Sun Yat sen Memorial Hospital of Sun Yat sen University Yang Chunmin, Deputy Director of Surgery at the Breast Center of Yixian Breast Cancer Hospital, Chief Nurse of the Breast Department at the University City Hospital of Guangdong Provincial Hospital of Traditional Chinese Medicine, has entered the new medical insurance catalog - "subcutaneous preparation" of trastuzumab to promote high-quality development of public hospitals. On December 13, 2023, the National Medical Insurance Administration announced the adjustment results of the national medical insurance catalog for 2023, with a total of 126 drugs newly added to the national medical insurance drug catalog, This includes 21 types of cancer drugs. In particular, the "subcutaneous preparation" of trastuzumab for breast cancer treatment was included in the list of new medical insurance, and was officially implemented on January 1, 2024. It is reported that trastuzumab is a HER2 targeted drug originally developed by Roche for the treatment of breast cancer and has been on the market for 20 years. Among breast cancer patients, HER2 positive breast cancer patients account for about 25%. This subtype has high malignancy and poor prognosis. At present, the "Toto double target regimen" of trastuzumab combined with Partouzumab has become the standard regimen for the treatment of HER2 positive breast cancer, and is in an unshakable position in the anti HER2 treatment. Subcutaneous preparations bring new development opportunities to public hospitals, which can further improve the turnover rate of daytime wards and hospitalizations, and effectively improve the utilization of medical resources. According to clinical statistics, the subcutaneous preparation of trastuzumab can save 81% of the single nursing time of medical staff and reduce 83% of the single visit time of patients. Professor Jia Weijuan believes that the reform of breast cancer treatment mode has greatly promoted the development of nursing system and chronic disease management pattern. "Nursing work will be greatly reduced. Firstly, nurses no longer need to dispense medication, and secondly, the 'subcutaneous' injection method is much simpler than intravenous injection. Perhaps in the near future, people can complete it at home like injecting insulin." Professor Yang Chunmin said: The change in dosage form means that patients stay in the hospital for a shorter period of time, and the service time of medical staff is also shortened accordingly. As a result, the labor cost of the hospital is greatly reduced, and medical staff can have more time and energy to study